Close Menu

NEW YORK (360Dx) — Clinical contract research firm Galaxy announced on Tuesday its launch, as well as a licensing deal for intellectual property covering blood-based biomarkers of stroke from Proteome Sciences.

According to McKinney, Texas-based Galaxy, the IP was generated by Proteome Sciences in partnership with the University of Geneva and Geneva University Hospitals, and will be used in the development of a point-of-care test for the diagnosis and timing of stroke onset to help inform treatment decisions.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.